[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652626":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":35,"locations":43,"responsibleParty":58,"collaborators":25,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":25,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":25,"enrollmentInfo":71,"targetDuration":25,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":82,"overallStatus":46,"whyStopped":25,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"University of Zurich","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Ambient air","EXPERIMENTAL","Patient will be assessed at University Hospital Zurich",[13],"Other: 6-minute walk distance (6MWD) test on ambient conditions",{"label":15,"type":16,"description":17,"interventionNames":18},"Liquid oxygen therapy via nasal canula","ACTIVE_COMPARATOR","Supplemental Liquid Oxygen Therapy (LOX) at approximately 4l\u002Fmin will be provided via nasal canula from a small oxygen tank at University Hospital Zurich to perform clinical assessments.",[19],"Other: 6-minute walk distance (6MWD) test with supplemental oxygen (LOX)",[21,26],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"6-minute walk distance (6MWD) test on ambient conditions","6-minute walk distance (6MWD) test will be performed on ambient air according to clinical standards",[9],null,{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"6-minute walk distance (6MWD) test with supplemental oxygen (LOX)","6-minute walk test(6MWT) test will be performed according to clinical standards with supplemental liquid oxygen therapy (LOX, approximately 4l\u002Fmin, nasal)",[15],[31],{"name":32,"affiliation":33,"role":34},"Silvia Ulrich, Prof. Dr. med.","University Hospital Zurich, Department of Pulmonology","PRINCIPAL_INVESTIGATOR",[36,40],{"name":32,"role":37,"phone":38,"phoneExt":25,"email":39},"CONTACT","+41442552220","silvia.ulrich@usz.ch",{"name":41,"role":37,"phone":38,"phoneExt":25,"email":42},"Mona Lichtblau, PD. Dr. med.","mona.lichtblau@usz.ch",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":25},"University Hospital Zurich","RECRUITING","Zurich","Canton of Zurich","8091","Switzerland","CH",{"type":53,"coordinates":54},"Point",[55,56],8.55,47.36667,{"lat":56,"lon":55},{"type":59,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"SPONSOR_INVESTIGATOR","Silvia Ulrich Somaini","Prof. Dr. med.","100652626","exercise-performance-on-ambient-air-vs-low-flow-liquid-oxygen-therapy-in-pulmonary-vascular-disease-pvd-100652626",false,"NCT07777445","Exercise Performance on Ambient Air vs. Low-Flow Liquid Oxygen Therapy in Pulmonary Vascular Disease (PVD)","Exercise Performance on Ambient Air vs. Commonly Prescribed Nasal Low Flow Oxygen Therapy in Patients With Exercise Induced Desaturation Due to Pulmonary Disease","Inclusion Criteria:\n\n* \\- Minimum 18 years of age\n* Written informed consent\n* Patients with diagnosed pulmonary arterial hypertension (PAH), distal chronic thromboembolic pulmonary hypertension (CTEPH), chronic obstructive pulmonary disease (COPD) with emphysema, COPD without emphysema, or interstitial lung disease\n* Former desaturation under exercise defined as SpO2-decrease \\>3%\n* Treated with a stable drug therapy (with no changes for at least 14 days prior to screening)\n\nExclusion Criteria:\n\n* \\- Severe hypoxemia needing supplemental oxygen therapy defined as PaO2 \\\u003C 6.9 kPa\n* Inability or contraindications to undergo the investigated intervention\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, walk disability etc.","ALL","18 Years",{"count":72,"type":73},40,"ESTIMATED","INTERVENTIONAL",[76],"NA","The investigators aim to study the effect of liquid oxygen therapy (4l\u002Fmin, nasal) )in Swiss residents with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH).",[79,80,81],"Pulmonary Vascular Disease","Chronic Thromboembolic Pulmonary Hypertension (CTEPH)","Pulmonary Arterial Hypertension (PAH)",[83,84,85,86,87],"Pulmonary Hypertension","Supplemental Oxygen Therapy","Pulmonary Arterial Hypertension","Chronic Thromboembolic Pulmonary Hypertension","6-Minute Walk Distance","2026-08-17",{"date":90,"type":91},"2026-08-20","ACTUAL",{"date":93,"type":73},"2026-08-01",{"date":95,"type":73},"2028-12-31",{"name":60,"class":6},1]